Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Ed­i­tor’s note: A pre­vi­ous ver­sion of this sto­ry mis­char­ac­ter­ized over­all sur­vival da­ta from the ALPINE study as hav­ing “missed” sta­tis­ti­cal sig­nif­i­cance and over­stat­ed the end­point’s im­por­tance with­in the con­text of chron­ic lym­pho­cyt­ic leukemia. This sto­ry has been up­dat­ed and cor­rect­ed. 

SAN DIEGO — BeiGene tout­ed longer fol­low-up da­ta for its can­cer drug Brukin­sa in re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia Sat­ur­day, show­ing con­tin­ued im­prove­ments in pro­gres­sion-free sur­vival com­pared to Ab­b­Vie and J&J’s Im­bru­vi­ca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER